PATENT CLAIM ANALYSIS

Application Number: 16181747
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "235500"]

Abstract:
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.

Claim (Index 12):
The method of  claim 1 , wherein the EZH2 inhibitor is administered orally.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 98.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15319535', '15809445', '15567838', '13949026', '14540977']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7642177325209775
- 35 USC 102 Novelty (BERT): 0.5462953680681698
- Combined Prediction Score: 0.7424254960756966
- Mean Citation Score: 269.48406600000004
- Max Citation Score: 384.1392
- Similarity Product: 377.8357073158265

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test